Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer
Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer
复制标题
DOI：
10.1023/a:1008375208574
复制
发表时间：
2000-07-01
影响因子：
50.5
通讯作者：
Ueyama, Y
中科院分区：
文献类型：
--
作者：
Hatanaka, H;Abe, Y;Ueyama, Y
背景资料：据报道，2型细胞因子白细胞介素（IL）-10可抑制针对各种肿瘤的局部免疫的抗肿瘤活性。某些肺癌产生IL-10，但IL-10表达的临床意义还不清楚。患者和方法：我们研究了IL-10和IL-10受体（IL-10 R）mRNA表达在82个非小细胞肺癌（NSCLC）的逆转录聚合酶链反应（RT-PCR）测定。结果：82例NSCLC手术标本中68例（83%）有IL-10 mRNA表达，其中腺癌40例（40/50），鳞癌22例（22/26），大细胞癌5例（5/5），腺鳞癌1例（1/1）。RT-PCR检测79例NSCLC中IL-10 R mRNA表达，阳性率为96.1%。通过IHC证实肿瘤细胞内的IL-10表达。12例IL-10 mRNA表达阳性的NSCLC患者血清中IL-10水平在0 ~ 2.99 pg/ml范围内无明显升高。结论：IL-10表达与NSCLC患者的临床预后有关，IL-10表达是影响NSCLC患者预后的一个重要因素。
Background: The type 2 cytokine interleukin (IL)-10 has been reported to inhibit the antitumour activity of the regional immunity against various neoplasms. Certain lung cancers produce IL-10, but the clinical significance of IL-10 expression is not well understood.Patients and methods: We examined IL-10 and IL-10 receptor (IL-10R) mRNA expression in 82 non-small-cell lung cancers (NSCLC) by reverse transcription-polymerase chain reaction (RT-PCR) assay. Immunohistochemistry (IHC) and enzyme immunoassay (EIA) were applied to evaluate the cellular localisation and the serum levels of IL-10.Results: RT-PCR assay revealed IL-10 mRNA expression in 68 (83%) of 82 NSCLC surgical specimens (40 of 50 adenocarcinomas, 22 of 26 squamous cell carcinomas, 5 of 5 large-cell carcinomas, 1 of 1 adenosquamous-cell carcinoma). RT-PCR assay also revealed IL-10R mRNA expression in 79 cases of NSCLC (96.1%). IL-10 expression was confirmed within tumour cells by IHC. EIA showed no significant serum IL-10 elevation in the 12 NSCLC positive for IL-10 mRNA expression (0-2.99 pg/ml). The NSCLC patients with IL-10 production showed significantly poorer prognosis than those without IL-10 production (P < 0.05, Kaplan-Meier, log-rank test).Conclusions: These results suggested that the cytoplasmic IL-10 correlated to clinical prognosis, and that IL-10 expression is a prognostic factor for NSCLC.